Zylox-Tonbridge Medical Technology Co., Ltd.

DB:818 Stock Report

Market Cap: €470.1m

Zylox-Tonbridge Medical Technology Past Earnings Performance

Past criteria checks 2/6

Zylox-Tonbridge Medical Technology has been growing earnings at an average annual rate of 16.5%, while the Medical Equipment industry saw earnings declining at 2.5% annually. Revenues have been growing at an average rate of 51.5% per year. Zylox-Tonbridge Medical Technology's return on equity is 0.8%, and it has net margins of 3.9%.

Key information

16.5%

Earnings growth rate

27.7%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate51.5%
Return on equity0.8%
Net Margin3.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zylox-Tonbridge Medical Technology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:818 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2466426276232
31 Mar 24596-27277246
31 Dec 23528-79278261
30 Sep 23470-101275266
30 Jun 23411-124272270
31 Mar 23373-119261252
31 Dec 22334-114249233
30 Sep 22297-135234223
30 Jun 22259-155219213
31 Mar 22219-178207191
31 Dec 21178-200196168
30 Sep 21137-168158131
30 Jun 2197-13511994
31 Mar 2162-1188583
31 Dec 2028-1005172
31 Dec 195-672453

Quality Earnings: 818 has a large one-off loss of CN¥19.3M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 818 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 818 has become profitable over the past 5 years, growing earnings by 16.5% per year.

Accelerating Growth: 818 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 818 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 818's Return on Equity (0.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:39
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zylox-Tonbridge Medical Technology Co., Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuo SongCitic Securities Co., Ltd.
null nullGuoyuan Securities (HK) Ltd
Youjue HuMorgan Stanley